B. Riley Securities Initiates Coverage On Denali Therapeutics with Buy Rating, Announces Price Target of $38
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has initiated coverage on Denali Therapeutics (NASDAQ:DNLI) with a Buy rating and a price target of $38.
September 06, 2023 | 12:37 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Denali Therapeutics has been given a Buy rating by B. Riley Securities with a price target of $38.
The Buy rating and price target set by B. Riley Securities indicates a positive outlook for Denali Therapeutics. This could potentially attract investors, driving up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100